Fibrogen announces completion of patient enrollment in lelantos-2, a phase 3 clinical study of pamrevlumab in duchenne muscular dystrophy

- 73 ambulatory dmd patients enrolled - - topline data anticipated 2h:2023 -
FGEN Ratings Summary
FGEN Quant Ranking